Antitumor and Adjuvant Activity of λ-carrageenan by Stimulating Immune Response in Cancer Immunotherapy

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Luo, Min ^a   Shao, Bin ^a   Nie, Wen ^a   Wei, Xia Wei ^a   Li, Yu Li ^a   Wang, Bi Lan ^a   He, Zhi Yao ^a   Liang, Xiao ^a   Ye, Ting Hong ^a   Wei, Yu Quan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CARRAGEENAN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 17; OVALBUMIN; TUMOR NECROSIS FACTOR;

ANIMAL; ANTIBODY SPECIFICITY; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; EXPERIMENTAL MELANOMA; IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; INTRALESIONAL DRUG ADMINISTRATION; METABOLISM; MOUSE; NEOPLASMS; PATHOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARRAGEENAN; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; IMMUNITY; IMMUNOTHERAPY; INJECTIONS, INTRALESIONAL; INTERLEUKIN-17; MELANOMA, EXPERIMENTAL; MICE; NEOPLASMS; ORGAN SPECIFICITY; OVALBUMIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84935012433     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11062     Document Type: Article

References (50)

1. Kerbel, R. S. A cancer therapy resistant to resistance. Nature 390, 335-336 (1997).
2. Siegel, R. et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 62, 220-241 (2012).
3. Gravitz, L. Cancer immunotherapy. Nature 504, S1-S1 (2013).
4. McNutt, M. Cancer Immunotherapy. Science 342, 1417-1417 (2013).
5. Topalian, S. L., Weiner, G. J. & Pardoll, D. M. Cancer immunotherapy comes of age. J. Clin. Oncol. 29, 4828-4836 (2011).
6. Moyer, M. W. New adjuvants aim to give whooping cough vaccine a boost. Nat. Med. 18, 991-991 (2012).
7. Reed, S. G., Orr, M. T. & Fox, C. B. Key roles of adjuvants in modern vaccines. Nat. Med. 19, 1597-1608 (2013).
8. McKee, A. S., Munks, M. W. & Marrack, P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity 27, 687-690 (2007).
9. Verdeil, G., Marquardt, K., Surh, C. D. & Sherman, L. A. Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy. P Natl Acad Sci. 105, 16683-16688 (2008).
10. Klinman, D. M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol. 4, 249-259 (2004).
11. Kumar, H., Koyama, S., Ishii, K. J., Kawai, T. & Akira, S. Cutting edge: cooperation of IPS-1-and TRIF-dependent pathways in poly IC-enhanced antibody production and cytotoxic T cell responses. J Immunol. 180, 683-687 (2008).
12. McSorley, S. J., Ehst, B. D., Yu, Y. & Gewirtz, A. T. Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo. J Immunol. 169, 3914-3919 (2002).
13. Gattinoni, L. et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 202, 907-912 (2005).
14. Afonso, L. et al. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263, 235-237 (1994).
15. Costa, L. et al. Biological activities of sulfated polysaccharides from tropical seaweeds. Biomed. Pharmacother. 64, 21-28 (2010).
16. Yende, S. R., Harle, U. N. & Chaugule, B. B. Therapeutic potential and health benefits of Sargassumspecies. Pharmacogn Rev. 8, 1 (2014).
17. Xue, M. et al. Anticancer properties and mechanisms of fucoidan on mouse breast cancer in vitro and in vivo. PLoS One 7, e43483 (2012).
18. Liang, W., Mao, X., Peng, X. & Tang, S. Effects of sulfate group in red seaweed polysaccharides on anticoagulant activity and cytotoxicity. Carbohydr. Polym. 101, 776-785 (2014).
19. Childs, J. et al. Phase II randomized study of combination immunotherapy with or without Polysaccharide Krestin (PSK®) concurrently with a HER2 ICD peptide-based vaccine and trastuzumab in patients with stage IV breast cancer. Cancer Res. 72, OT3-1-02 (2012).
20. Kim, H. S. et al. Adjuvant effect of a natural TLR4 ligand on dendritic cells (P4240). J Immunol. 190, 47-48 (2013).
21. Santos, G. Carrageenans of species of Eucheuma J. Agardh and Kappaphycus Doty (Solieriaceae, Rhodophyta). Aquat. Bot. 36, 55-67 (1989).
22. Güven, K., Özsoy, Y. & Ulutin, O. Anticoagulant, fibrinolytic and antiaggregant activity of carrageenans and alginic acid. Bot. Mar. 34, 429-432 (1991).
23. Huang, G.-J., Pan, C.-H. & Wu, C.-H. Sclareol exhibits anti-inflammatory activity in both lipopolysaccharide-stimulated macrophages and the λ -carrageenan-induced Paw Edema model. J. Nat. Prod. 75, 54-59 (2012).
24. Wang, Q. et al. Vitamin D inhibits COX-2 expression and inflammatory response by targeting thioesterase superfamily member 4. J. Biol. Chem., jbc. M113. 517-581 (2014).
25. Zhou, G. et al. In vivo growth-inhibition of S180 tumor by mixture of 5-Fu and low molecular lambda-carrageenan from Chondrus ocellatus. Pharmacol. Res. 51, 153-157 (2005).
26. Zhou, G., Sheng, W., Yao, W. & Wang, C. Effect of low molecular lambda-carrageenan from Chondrus ocellatus on antitumor H-22 activity of 5-Fu. Pharmacol. Res. 53, 129-134 (2006).
27. Zhang, Y. Q., Tsai, Y. C., Monie, A., Hung, C. F. & Wu, T. C. Carrageenan as an adjuvant to enhance peptide-based vaccine potency. Vaccine 28, 5212-5219 (2010).
28. Janeway Jr, C. A. & Medzhitov, R. Innate immune recognition. Sci Signal. 20, 197 (2002).
29. Simms, P. E. & Ellis, T. M. Utility of flow cytometric detection of CD69 expression as a rapid method for determining poly-and oligoclonal lymphocyte activation. Clin. Diagn. Lab. Immunol. 3, 301-304 (1996).
30. Zou, W. & Restifo, N. P. T(H)17 cells in tumour immunity and immunotherapy. Nat. Rev. Immunol. 10, 248-256 (2010).
31. Gearing, A. et al. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 370, 555-557 (1994).
32. Baud, V. & Karin, M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 11, 372-377 (2001).
33. Carswell, E. et al. An endotoxin-induced serum factor that causes necrosis of tumors. P Natl Acad Sci. 72, 3666-3670 (1975).
34. Hu, D. E., Kettunen, M. I. & Brindle, K. M. Monitoring T-lymphocyte trafficking in tumors undergoing immune rejection. Magn. Reson. Med. 54, 1473-1479 (2005).
35. Li, Y. et al. Irradiated tumor cells of lipopolysaccharide stimulation elicit an enhanced anti-tumor immunity. J. Cancer Res. Clin. Oncol. 140, 1815-1823 (2014).
36. Jung, I. D. et al. Enhanced efficacy of therapeutic cancer vaccines produced by co-treatment with Mycobacterium tuberculosis heparin-binding hemagglutinin, a novel TLR4 agonist. Cancer Res. 71, 2858-2870 (2011).
37. Narayanan, P. et al. A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy. J. Clin. Invest. 121, 1524-1534 (2011).
38. Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423-1437 (2013).
39. Vasievich, E. A. & Huang, L. The suppressive tumor microenvironment: a challenge in cancer immunotherapy. Mol. Pharm. 8, 635-641 (2011).
40. Gajewski, T. F. et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr. Opin. Immunol. 25, 268-276 (2013).
41. Shirota, H. & Klinman, D. M. Use of CpG oligonucleotides for cancer immunotherapy and their effect on immunity in the tumor microenvironment. Immunotherapy 5, 787-789 (2013).
42. Solinas, G. et al. Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. J Immunol. 185, 642-652 (2010).
43. Castells, M., Thibault, B., Delord, J.-P. & Couderc, B. Implication of tumor microenvironment in chemoresistance: tumorassociated stromal cells protect tumor cells from cell death. Int J Mol Sci. 13, 9545-9571 (2012).
44. Sica, A. & Bronte, V. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117, 1155 (2007).
45. Li, L. et al. The chemokine receptors CCR2 and CX3CR1 mediate monocyte/macrophage trafficking in kidney ischemiareperfusion injury. Kidney Int. 74, 1526-1537 (2008).
46. Wynn, T. A., Chawla, A. & Pollard, J. W. Macrophage biology in development, homeostasis and disease. Nature 496, 445-455 (2013).
47. Sica, A. et al. Macrophage polarization in tumour progression. Semin Cancer Biol. 18, 349-355 (2008).
48. Kryczek, I. et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114, 1141-1149 (2009).
49. Martin-Orozco, N. et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31, 787-798 (2009).
50. Malley, R. et al. Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide. Infect. Immun. 74, 2187-2195(2006).